Patent · US Active

FGF21 compound / GLP-1R agonist combinations with optimized activity ratio

US10583174B2 · kind B2 · utility

2Cited by

1References

22Claims

0Family size

Assignee

Sanofi · FR

Inventors

Britta GÖBEL · Frankfurt am Main, DE
Mark Sommerfeld · Frankfurt am Main, DE
Oliver BOSCHEINEN · Frankfurt, DE
Thomas LANGER · Frankfurt am Main, DE
Christine RUDOLPH · Nierstein, DE
Andreas Evers · Frankfurt am Main, DE

Key dates

Filing date	Dec 22, 2017
Grant date	Mar 10, 2020
Priority date	—
Expiry date	Dec 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.